57543-67-6

Basic information

• Product Name: 6-CHLORO-2H-CHROMENE-3-CARBONITRILE
• Synonyms: BUTTPARK 48\08-16;6-CHLORO-2H-CHROMENE-3-CARBONITRILE
• CAS NO: 57543-67-6
• Molecular Formula: C₁₀H₆ClNO
• Molecular Weight: 191.61
• Mol File: 57543-67-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 135-137°
• Boiling Point: 346.7 °C at 760 mmHg
• Flash Point: 163.5 °C
• Appearance: /
• Density: 1.35 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-CHLORO-2H-CHROMENE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-2H-CHROMENE-3-CARBONITRILE(57543-67-6)
• EPA Substance Registry System: 6-CHLORO-2H-CHROMENE-3-CARBONITRILE(57543-67-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 57543-67-6(Hazardous Substances Data)

Usage

General Description

6-Chloro-2H-chromene-3-carbonitrile is a chemical compound with the molecular formula C10H5ClNO. It is a nitrile derivative of chromene, and it is commonly used in the pharmaceutical and agrochemical industries as a building block for the synthesis of various compounds. 6-CHLORO-2H-CHROMENE-3-CARBONITRILE has a chloro group at the 6th position of the chromene ring and a nitrile group at the 3rd position, making it a versatile intermediate for the production of biologically active molecules. It has also been studied for its potential biological activities, including its antimicrobial and anti-inflammatory properties. Overall, 6-Chloro-2H-chromene-3-carbonitrile is an important chemical for the synthesis of various compounds and has potential applications in the fields of medicine and agriculture.

Upstream product

• 107-13-1 acrylonitrile 
• 635-93-8 5-chlorosalicyclaldehyde 

Downstream Products

• 83823-06-7 6-chloro-2H-1-benzopyran-3-carboxylic acid 
• 306935-54-6 6-chloro-2H-1-benzopyran-3-carboxylic acid chloride 
• 83823-20-5 6-Chloro-2H-chromene-3-carboxylic acid methylamide 
• 83823-22-7 (6-Chloro-2H-chromen-3-yl)-(2-imino-2H-pyridin-1-yl)-methanone 
• 83823-23-8 (6-Chloro-2H-chromen-3-yl)-(4-imino-4H-pyridin-1-yl)-methanone 
• 1417440-75-5 3-(6-chloro-2H-chromen-3-yl)-5-(3-methoxyphenyl)-1,2,4-oxadiazole 
• 1417440-74-4 5-(4-tert-butylphenyl)-3-(6-chloro-2H-chromen-3-yl)-1,2,4-oxadiazole 
• 1417440-73-3 3-(6-chloro-2H-chromen-3-yl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole 
• 1417440-70-0 3-(6-chloro-2H-chromen-3-yl)-5-(3,4-difluorophenyl)-1,2,4-oxadiazole 
• 1417440-69-7 3-(6-chloro-2H-chromen-3-yl)-5-(4-ethoxyphenyl)-1,2,4-oxadiazole 
• 1417440-68-6 3-(6-chloro-2H-chromen-3-yl)-5-(3-fluorophenyl)-1,2,4-oxadiazole 
• 1417440-67-5 5-benzyl-3-(6-chloro-2H-chromen-3-yl)-1,2,4-oxadiazole 
• 1417440-66-4 5-(4-bromophenyl)-3-(6-chloro-2H-chromen-3-yl)-1,2,4-oxadiazole 
• 1195865-02-1 (Z)-6-chloro-3-ethoxymethyl-2-phenylimino-2H-chromene 

Relevant articles and documents

3-nitro-2H-chromenes as a new class of inhibitors against thioredoxin reductase and proliferation of cancer cells

A series of 3-nitrochromenes were designed and synthesized. These compounds showed good inhibitory activity against thioredoxin reductase (TrxR) and the proliferation of A549 cancer cells. The structure-activity relationship analysis indicates that the 3-nitrochromene scaffold is the crucial pharmacophore for achieving good inhibitory activity. The bromo-substitutions at the 6- and 8-position of 3-nitrochromene significantly increase the inhibitory activity. A series of 3-nitrochromenes were designed and synthesized. They showed good inhibitory activity against thioredoxin reductase and the proliferation of A549 cancer cells. Structure-activity relationship analysis revealed that the 3-nitrochromene scaffold is the crucial pharmacophore for achieving good inhibitory activity. Bromo-substitutions at the 6- and 8-position of 3-nitrochromene significantly increase the inhibitory activity. Copyright

DUAL AGONISTS OF FXR AND PPARδ AND THEIR USES

The present invention relates to small molecule compounds and their use as agonists of farnesoid X receptor (FXR) and/or peroxisome proliferator activated receptor delta (PPARδ). The present invention also relates to the use of said compounds in the treatment of metabolic diseases and respective methods of treatment.

Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors

ROCK1 and ROCK2 are highly homologous isoforms. Accumulated studies indicate that they have distinct different functions, and the development of isoform selective ROCK inhibitors will pave new roads for the treatment of various diseases. In this work, a series of amide-chroman derivatives were synthesized and biologically evaluated in order to develop potent and isoform selective ROCK2 inhibitors. Remarkably, (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide ((S)-7c) possessed ROCK2 inhibitory activity with an IC50 value of 3 nM and 22.7-fold isoform selectivity (vs. ROCK1). Molecular docking indicated that hydrophobic interactions were the key element for the high potency and isoform selectivity of (S)-7c. The binding free energies predicted by MM/GBSA were in good agreement with the experimental bioactivities, and the analysis of individual energy terms suggested that residue Lys105 in ROCK1 or Lys121 in ROCK2 was the key residue for the isoform selectivity of (S)-7c.